Monitor whether FDA actually receives additional funding or resources for this directive—executive orders directing agencies to 'expedite' without appropriations are often symbolic gestures that fade without Congressional budget action.
This executive order directs FDA to expedite existing research processes but creates no constitutional harm—it's a policy preference within executive authority over agency priorities. The high media coverage relative to governance substance (B=36, A=0) and the feel-good veteran/PTSD framing suggest this functions primarily as positive spectacle and credit-claiming for a bipartisan-adjacent issue, generating headlines without meaningful institutional change.